{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T23:32:06Z","timestamp":1768692726120,"version":"3.49.0"},"reference-count":74,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2009,4,17]],"date-time":"2009-04-17T00:00:00Z","timestamp":1239926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:p>Chemotherapy, radiation, and surgery are the conventional treatment modalities for cancer. The success achieved with these approaches has been limited due to several factors like chemoresistance to drugs, non\u2010specificity leading to peripheral toxicity, and non\u2010resectable tumors. To combat these problems, the concept of targeted therapy using immunotoxins was developed. Immunotoxins are chimeric proteins with a cell\u2010selective ligand chemically linked or genetically fused to a toxin moiety and can target cancer cells overexpressing tumor\u2010associated antigens, membrane receptors, or carbohydrate antigens. Ligands for these receptors or monoclonal antibodies or single chain variable fragments directed against these antigens are fused with bacterial or plant toxins and are made use of as immunotoxins. Pseudomonas exotoxin, anthrax toxin, and diphtheria toxin are the commonly used bacterial toxins. Ricin, saporin, gelonin, and poke weed antiviral protein are the plant toxins utilized in immunotoxin constructs. Several such fusion proteins are in clinical trials, and denileukin difitox is a FDA\u2010approved fusion protein. In spite of the promise shown by bacterial\u2010 and plant toxin\u2010based chimeric proteins, their clinical application is hampered by several factors like immunogenicity of the toxin moiety and non\u2010specific toxicity leading to vascular leak syndrome. In order to overcome these problems, a novel generation of immunotoxins in which the cytotoxic moiety is an endogenous protein of human origin like proapoptotic protein or RNase has been developed. This review summarizes the advances in this new class of fusion protein and the future directions to be explored. (<jats:italic>Cancer Sci<\/jats:italic> 2009)<\/jats:p>","DOI":"10.1111\/j.1349-7006.2009.01192.x","type":"journal-article","created":{"date-parts":[[2009,4,17]],"date-time":"2009-04-17T09:29:15Z","timestamp":1239960555000},"page":"1359-1365","source":"Crossref","is-referenced-by-count":130,"title":["Humanized immunotoxins: A new generation of immunotoxins for targeted cancer therapy"],"prefix":"10.1111","volume":"100","author":[{"given":"Mrudula","family":"Mathew","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rama S.","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,7,10]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"596","volume-title":"The Collected Papers of Paul Ehrlich","author":"Ehrlich P.","year":"1956"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-419X(97)00021-8"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1208\/aapsj080363"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2008.06.017"},{"key":"e_1_2_5_6_2","first-page":"571","article-title":"FDA approves fusion protein for treatment of lymphoma","volume":"39","author":"Piascik P.","year":"1999","journal-title":"J Am Pharm Assoc"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1216-3"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1006\/clim.2001.5066"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1089\/cdd.1987.4.245"},{"key":"e_1_2_5_10_2","first-page":"345","article-title":"Antimelanoma monoclonal antibody ricin A chain immunoconjugate (XMMME\u2010001\u2010RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial","volume":"9","author":"Oratz R","year":"1990","journal-title":"J Biol Response Mod"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199304000-00007"},{"key":"e_1_2_5_12_2","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.4049\/jimmunol.159.10.5168","article-title":"Prevention of immunotoxin\u2010induced immunogenicity by coadministration with CTLA4Ig enhances antitumor efficacy","volume":"159","author":"Siegall CB","year":"1997","journal-title":"J Immunol"},{"key":"e_1_2_5_13_2","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.4049\/jimmunol.146.6.1806","article-title":"Suppression of the immune response to immunotoxins with anti\u2010CD4 monoclonal antibodies","volume":"146","author":"Jin FS","year":"1991","journal-title":"J Immunol"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.140210597"},{"key":"e_1_2_5_15_2","first-page":"116","article-title":"Design of a genetic immunotoxin to eliminate toxin immunogenicity","volume":"2","author":"Chen SY","year":"1995","journal-title":"Gene Ther"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/01926230701320337"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.2.414"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/35051606"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-0004(00)01740-0"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc883"},{"key":"e_1_2_5_21_2","first-page":"559","article-title":"BAX\u2010induced cell death may not require interleukin 1\u03b2\u2010converting enzyme\u2010like proteases","volume":"14","author":"Xiang J","year":"1993","journal-title":"Proceedings of the Natl Acad Sci USA"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.9.4997"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(99)01050-9"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1009689529756"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(98)79298-X"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(04)00258-8"},{"key":"e_1_2_5_27_2","first-page":"1179","article-title":"Using apoptosis for targeted cancer therapy by a new gonadotropin releasing hormone\u2013DNA fragmentation factor 40 chimeric protein","volume":"9","author":"Yehudah BA","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.176.6.1521"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90376-X"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.186.8.1323"},{"key":"e_1_2_5_31_2","first-page":"949","article-title":"Mechanistic studies of a novel, human fusion toxin composed of vascular endothelial growth factor (VEGF) 121 and the serine protease granzyme B: directed apoptotic events in vascular endothelial cells","volume":"2","author":"Liu Y","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4401773"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1593\/neo.05556"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90068-3"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.22.12687"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4401187"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80212-5"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80211-3"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.277.5327.815"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2774"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11702"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1593\/neo.04229"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M413673200"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-2756"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/364806a0"},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830250821"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.187.8.1205"},{"key":"e_1_2_5_48_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2929"},{"key":"e_1_2_5_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(03)00225-4"},{"key":"e_1_2_5_50_2","first-page":"57","article-title":"Phase 1 human clinical trial of ONCONASE (P\u201030 protein) administered intravenously on a weekly schedule in cancer patients with solid tumors","volume":"3","author":"Mikulski SM","year":"1993","journal-title":"Int J Oncol"},{"key":"e_1_2_5_51_2","unstructured":"MikulskiSM.Phase II trial of onconase in patients with advanced malignant mesothelioma: analysis of survival. Fifth International Meeting on Ribonucleases May 12\u201316 1999; Warrenton VA."},{"key":"e_1_2_5_52_2","doi-asserted-by":"publisher","DOI":"10.1006\/excr.1999.4718"},{"key":"e_1_2_5_53_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00508a035"},{"key":"e_1_2_5_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(84)90306-3"},{"key":"e_1_2_5_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1380-2933(97)00070-5"},{"key":"e_1_2_5_56_2","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/11.12.1285"},{"key":"e_1_2_5_57_2","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/12.11.1013"},{"key":"e_1_2_5_58_2","doi-asserted-by":"publisher","DOI":"10.1006\/cyto.1999.0619"},{"key":"e_1_2_5_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(02)02527-9"},{"key":"e_1_2_5_60_2","doi-asserted-by":"publisher","DOI":"10.1007\/s000180050208"},{"key":"e_1_2_5_61_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.3771.641"},{"key":"e_1_2_5_62_2","doi-asserted-by":"crossref","first-page":"26\u00a0739","DOI":"10.1016\/S0021-9258(18)47081-0","article-title":"Expression and characterization of recombinant human eosinophil\u2010derived neurotoxin and eosinophil\u2010derived neurotoxin\u2010anti\u2010transferrin receptor sFv","volume":"269","author":"Newton DL","year":"1994","journal-title":"J Biol Chem"},{"key":"e_1_2_5_63_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jbchem.a003281"},{"key":"e_1_2_5_64_2","first-page":"306","article-title":"Growth inhibition of mammalian cells by eosinophil cationic protein","volume":"269","author":"Maeda T","year":"2002","journal-title":"FEBS J"},{"key":"e_1_2_5_65_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00360a008"},{"key":"e_1_2_5_66_2","doi-asserted-by":"crossref","first-page":"21\u00a0982","DOI":"10.1016\/S0021-9258(19)36710-9","article-title":"Angiogenin is a cytotoxic, tRNA specific ribonuclease in the RNase A superfamily","volume":"267","author":"Saxena SK","year":"1992","journal-title":"J Biol Chem"},{"key":"e_1_2_5_67_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1711720203"},{"key":"e_1_2_5_68_2","first-page":"2703","article-title":"Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness","volume":"56","author":"Shimoyama S","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_5_69_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01214669"},{"key":"e_1_2_5_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(99)00077-6"},{"key":"e_1_2_5_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(99)00154-4"},{"key":"e_1_2_5_72_2","first-page":"8737","article-title":"Human angiogenin fused to human CD30 ligand (Ang\u2013CD30L) exhibits specific cytotoxicity against CD30\u2010positive lymphoma","volume":"61","author":"Huhn M","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_5_73_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603010"},{"key":"e_1_2_5_74_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302672"},{"key":"e_1_2_5_75_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-1160"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2009.01192.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2009.01192.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T02:38:20Z","timestamp":1697423900000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2009.01192.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,10]]},"references-count":74,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1111\/j.1349-7006.2009.01192.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2009.01192.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,10]]}}}